Akorn Inc (AKRX):製薬・医療:M&Aディール及び事業提携情報

GlobalDataが発行した調査報告書(DATA904C10015)
◆英語タイトル:Akorn Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10015
◆発行会社(リサーチ会社):GlobalData
◆発行日:2018年11月
◆ページ数:50
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Akorn Inc (Akorn) develops, manufactures, and commercializes generic and branded prescription pharmaceuticals and branded and over-the-counter consumer health products and animal health pharmaceuticals. The company offers its products in both sterile and non-sterile dosage forms including oral liquids, otics, ophthalmics, injectables, topicals, inhalants, and nasal sprays. It also offers contract manufacturing services. Akorn caters to physicians, surgery centers, clinics, optometrists, hospitals, long-term care, wholesalers, retail pharmacies, group purchasing organizations and other pharmaceutical companies. The company has manufacturing facilities in India and the US. It operates in the US, Canada, Mauritius, Luxembourg, Switzerland and India. Akorn is headquartered in Lake Forest, Illinois, the US.

Akorn Inc (AKRX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akorn Inc, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13
Oak Pharma Acquires Tafluprost Business from Merck 14
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15
Akorn Acquires Betimol, Opthalmic Drug, From Santen 16
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19
Partnerships 20
Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20
Knight Therapeutics Enters into Distribution Agreement with Akorn 21
Licensing Agreements 22
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22
Santen Pharma Enters into Licensing Agreement with Oak Pharma 23
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25
Asset Transactions 26
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26
Acquisition 28
Hi-Tech Pharma Acquires FormuTech Nutrition 28
Hi-Tech Pharma to Acquire Advanced Pharma 29
Akorn Acquires Excelvision for USD25.9 Million 30
Akorn Acquires VersaPharm from Tailwind Capital Partners 31
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33
Akorn Completes Acquisition Of Hi-Tech Pharmacal For US$640 Million 34
Akorn Acquires Inspire Pharma From Merck For US$53 Million 36
Serum Institute Plans To Sell Its Stake In Akorn 38
Akorn Inc – Key Competitors 40
Akorn Inc – Key Employees 41
Akorn Inc – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 43
Recent Developments 44
Financial Announcements 44
Nov 06, 2018: Akorn provides third quarter 2018 results 44
Mar 01, 2017: Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance 45
Legal and Regulatory 47
Oct 01, 2018: Akorn comments on Delaware Chancery Court Ruling 47
Feb 26, 2018: Akorn Issues Statement on Investigation 48
Feb 09, 2018: Kyros Law is Filing Compensation Claims on Behalf of Akorn Pharmaceuticals Investors 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50

List of Tables
Akorn Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10
Akorn Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Akorn Acquires Xopenex Inhalation Solution from Sunovion Pharma for USD45 Million 13
Oak Pharma Acquires Tafluprost Business from Merck 14
Akorn Acquires Rights to Zioptan from Merck Sharp & Dohme 15
Akorn Acquires Betimol, Opthalmic Drug, From Santen 16
Hi-Tech Pharmacal Acquires Rights To Cormax From Watson Labs 17
Hi-Tech Pharmacal Acquires Homeopathic Nasal Spray Products From Dynova Labs 18
Akorn Completes Acquisition Of Manufacturing Assets Of Kilitch Drugs 19
Hi-Tech Pharma Forms Joint Venture with Shanghai Yongyi Biotech 20
Knight Therapeutics Enters into Distribution Agreement with Akorn 21
Shenzhen Hybio Pharma Enters into Licensing Agreement with Akorn 22
Santen Pharma Enters into Licensing Agreement with Oak Pharma 23
Hi-Tech Pharmacal Enters Into Licensing Agreement With Septodont For Lidocaine 5% Ointment 24
Hi-Tech Pharmacal Enters Into Licensing Agreement With Glycobiosciences For Hylase Wound Gel 25
Actavis Acquires Four Generic Products From Akorn And Hi-Tech Pharmacal 26
Hi-Tech Pharma Acquires FormuTech Nutrition 28
Hi-Tech Pharma to Acquire Advanced Pharma 29
Akorn Acquires Excelvision for USD25.9 Million 30
Akorn Acquires VersaPharm from Tailwind Capital Partners 31
Valeant Pharma Acquires ECR Pharma from Akorn for USD41 Million 33
Akorn Completes Acquisition Of Hi-Tech Pharmacal For US$640 Million 34
Akorn Acquires Inspire Pharma From Merck For US$53 Million 36
Serum Institute Plans To Sell Its Stake In Akorn 38
Akorn Inc, Key Competitors 40
Akorn Inc, Key Employees 41
Akorn Inc, Subsidiaries 42
Akorn Inc, Joint Venture 43

List of Figures
Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Akorn Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Akorn Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Akorn Inc, Medical Devices Deals, 2012 to YTD 2018 10

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Akorn Inc (AKRX):製薬・医療:M&Aディール及び事業提携情報(Akorn Inc (AKRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆